KRAS and neoplasm: To further investigate the functional characteristics of B13.14.1 TCR-engineered T cells, we carried out a tumor cell line killing assay with autologous LCL cells or SW620-CIITA-DPB1*03:01 loaded with different concentrations of KRAS G12V-T15 peptide (TEYKLVVVGAVGV) and corresponding wild type peptide (TEYKLVVVGAGGV), i.e., 10 μg/ml, 1 μg/ml, 0.1 μg/ml, 0.01 μg/ml, 0.001 μg/ml.